For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Compass Therapeutics Inc (NASDAQ: CMPX) closed the day trading at $3.05 down -3.79% from the previous closing price of $3.17. In other words, the price has decreased by -$3.79 from its previous closing price. On the day, 0.91 million shares were traded. CMPX stock price reached its highest trading level at $3.3485 during the session, while it also had its lowest trading level at $3.025.
Ratios:
For a better understanding of CMPX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.33 and its Current Ratio is at 8.33. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.06.
On April 02, 2025, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform but kept the price unchanged to $6.
On February 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $12.Guggenheim initiated its Buy rating on February 24, 2025, with a $12 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 27 ’25 when Schuetz Thomas J. bought 10,000 shares for $2.11 per share. The transaction valued at 21,100 led to the insider holds 6,480,825 shares of the business.
GORDON CARL L sold 3,571,428 shares of CMPX for $5,678,571 on Apr 09 ’25. The Director now owns 0 shares after completing the transaction at $1.59 per share. On Apr 09 ’25, another insider, ORBIMED ADVISORS LLC, who serves as the Director of the company, sold 3,571,428 shares for $1.59 each. As a result, the insider received 5,678,571 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CMPX now has a Market Capitalization of 421760096 and an Enterprise Value of 315507616. For the stock, the TTM Price-to-Sale (P/S) ratio is 496.19 while its Price-to-Book (P/B) ratio in mrq is 3.82. Its current Enterprise Value per Revenue stands at 371.185 whereas that against EBITDA is -5.151.
Stock Price History:
The Beta on a monthly basis for CMPX is 1.31, which has changed by 2.062249 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, CMPX has reached a high of $4.08, while it has fallen to a 52-week low of $0.87. The 50-Day Moving Average of the stock is 17.80%, while the 200-Day Moving Average is calculated to be 37.79%.
Shares Statistics:
Over the past 3-months, CMPX traded about 826.69K shares per day on average, while over the past 10 days, CMPX traded about 745680 shares per day. A total of 138.28M shares are outstanding, with a floating share count of 87.95M. Insiders hold about 36.40% of the company’s shares, while institutions hold 43.13% stake in the company. Shares short for CMPX as of 1752537600 were 7842888 with a Short Ratio of 9.49, compared to 1749772800 on 7389202. Therefore, it implies a Short% of Shares Outstanding of 7842888 and a Short% of Float of 10.75.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A comprehensive evaluation of Compass Therapeutics Inc (CMPX) is underway, with the input of 7.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.09 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.39 and -$0.56 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is -$0.52, with 7.0 analysts recommending between -$0.25 and -$0.67.
